Author pages are created from data sourced from our academic publisher partnerships and public sources.
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has been used as a successful salvage and in postremission therapy but not as initial induction treatment.… Expand
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma
The combination of fludarabine, cyclophosphamide, and rituximab (FC‐R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity.
Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma.
A study of 260 patients with non-Hodgkin's lymphoma (NHL) who underwent bilateral bone marrow biopsy at initial diagnosis showed marrow disease in 99 (38%) cases. The highest incidence of disease… Expand
Sinus Arrhythmia in Acute Myocardial Infarction
Sinus arrhythmia, defined by means of a calculation of variance of die R‐R interval on admission to hospital, was present in. 73 of 176 patients admitted to a coronary care unit with acute myocardial… Expand
Clinical factors influencing the efficacy of pooled platelet transfusions
To determine the relative importance of clinical factors on the efficacy of platelet transfusions, 941 pooled platelet transfusions from HLA-unmatched donors were studied prospectively in 133… Expand
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
Sixteen patients with relapsed mantle-cell lymphoma (MCL) were treated with the combination of fludarabine and cyclophosphamide (FC) with or without rituximab. All patients had received prior CHOP… Expand
Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma
- S. Chua, J. Seymour, J. Streater, M. Wolf, E. Januszewicz, H. Prince
- Leukemia & lymphoma
- 1 January 2002
Central nervous system (CNS) relapse of non-Hodgkin's lymphoma (NHL) is usually fatal despite therapy and effective prophylaxis is desirable. Patients at high-risk usually receive intrathecal (IT)… Expand
The definition of refractoriness to platelet transfusions
- J. Bishop, J. Matthews, K. Yuen, K. McGrath, M. Wolf, J. Szer
- Transfusion medicine
- 1 March 1992
SUMMARY. The relationship between the 1 and 20 h post‐transfusion platelet count and three parameters used to define refractory transfusions, namely the corrected increment (CI), platelet increment… Expand
Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma.
- J. Campbell, J. Matthews, J. Seymour, M. Wolf, S. Juneja
- Annals of oncology : official journal of the…
- 1 February 2003
BACKGROUND The National Cancer Institute has recommended a bone marrow biopsy length of >/=20 mm for the staging and surveillance of patients with non-Hodgkin's lymphoma. However, there are few… Expand
Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.
- K. J. Tack, T. Littlejohn, G. Mailloux, M. Wolf, C. Keyserling
- Clinical therapeutics
- 1 March 1998
Because of increasing resistance to older antimicrobial agents, newer drugs need to be evaluated for the treatment of skin and skin-structure infections (SSSIs). This double-masked, randomized,… Expand